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Abstract
Spinal muscular atrophy is a severe motor neuron disease caused by inactivating mutations in the SMN1 gene leading to
reduced levels of full-length functional SMN protein. SMN is a critical mediator of spliceosomal protein assembly, and
complete loss or drastic reduction in protein leads to loss of cell viability. However, the reason for selective motor neuron
degeneration when SMN is reduced to levels which are tolerated by all other cell types is not currently understood.
Widespread splicing abnormalities have recently been reported at end-stage in a mouse model of SMA, leading to the
proposition that disruption of efficient splicing is the primary mechanism of motor neuron death. However, it remains
unclear whether splicing abnormalities are present during early stages of the disease, which would be a requirement for a
direct role in disease pathogenesis. We performed exon-array analysis of RNA from SMN deficient mouse spinal cord at 3
time points, pre-symptomatic (P1), early symptomatic (P7), and late-symptomatic (P13). Compared to littermate control
mice, SMA mice showed a time-dependent increase in the number of exons showing differential expression, with minimal
differences between genotypes at P1 and P7, but substantial variation in late-symptomatic (P13) mice. Gene ontology
analysis revealed differences in pathways associated with neuronal development as well as cellular injury. Validation of
selected targets by RT–PCR confirmed the array findings and was in keeping with a shift between physiologically occurring
mRNA isoforms. We conclude that the majority of splicing changes occur late in SMA and may represent a secondary effect
of cell injury, though we cannot rule out significant early changes in a small number of transcripts crucial to motor neuron
survival.
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Introduction
Autosomal recessive Spinal Muscular Atrophy (SMA) is a
leading genetic cause of infant mortality, with a carrier frequency
of 1:50 and an annual incidence of 1 in 10,000 live births [1].
Affected individuals develop symmetrical, proximal weakness
resulting from neurogenic muscle atrophy, and ultimately leading,
in the most severely affected individuals, to death from respiratory
failure. The pathological correlate of these symptoms is selective
loss of large alpha motor neurons in the ventral horn of the spinal
cord. The vast majority of cases are caused by homozygous
deletion of the survival motor neuron 1 (SMN1) gene [2] with
subsequent reduction in levels of the SMN protein [3]. SMN is
highly conserved in evolution and ubiquitously expressed.
Complete loss of SMN, which is incompatible with life [4], is
prevented by production of SMN from the SMN2 gene, a near
identical paralogue of SMN1 which has arisen from an inverted
duplication event in recent evolution. The presence of a
translationally silent C-T transition in SMN2 exon 7, however,
leads to disruption of an exonic splice-enhancer (ESE) element and
exon 7 skipping in the majority of SMN2 derived transcripts [5,6].
The functional consequence is that SMN2 produces only very little
full length SMN (FL-SMN), while the SMND7 isoform is
translated into an unstable protein that is rapidly degraded [7].
Disease severity is broadly proportional to residual SMN levels,
which is a function of SMN2 copy number, although other
modifying factors are involved in some cases [8,9].
The mechanism by which SMN deficiency leads to selective
lower motor neuron loss in SMA is poorly understood and difficult
to reconcile with its ubiquitous expression unless either SMN has a
motor neuron-specific function or motor neurons are selectively
vulnerable to a deficiency in the general function of SMN
common to all cells. Currently, the best characterised function of
SMN is as part of a multi-protein complex which is critical for the
core steps in the assembly of small nuclear ribonuclear proteins
(snRNPs), components of the spliceosome, the cellular machinery
that controls splicing of pre-mRNAs [10,11]. In particular, SMN
acts in the cytoplasmic assembly of Sm core proteins on snRNAs,
which is a prerequisite for import of snRNPs into the nucleus [12].
SMN levels and the activity of snRNP assembly vary during
PLoS Genetics | www.plosgenetics.org 1 December 2009 | Volume 5 | Issue 12 | e1000773development and according to tissue type. In the mouse spinal
cord, snRNP assembly is highest during embryogenesis and early
postnatal development and then falls to a baseline level when
myelination occurs [13]. Mouse models of SMA, which have
reduced SMN levels, show a drop in snRNP assembly activity as
measured by in vitro assays, while steady state snRNP levels
measured in tissues are only mildly reduced [14]. Interestingly, a
subset of snRNPs belonging to the minor spliceosome seems to be
differentially affected [14,15]. Several strands of evidence support
the notion that reduced snRNP assembly is associated with motor
neuron degeneration. The subtle motor neuron loss that has been
reported by some investigators at late stages in mice heterozygous
null for Smn can be accelerated by crossing with mice heterozygous
null for Gemin2, another core component of the SMN complex.
This is associated with a reduction in snRNP assembly [16]. In
zebrafish, a failure of embryonic motor axon growth can be
induced by silencing not only SMN, but also gemin2. The
observed defects can be rescued by direct injection of U snRNPs
[17]. However, other studies in zebrafish indicate that the axonal
degeneration phenotype is not coupled to U snRNP assembly [18].
Reducing SMN levels in HeLa cells by RNAi leads to an increased
error rate in splice-site pairing, which has also been observed in
fibroblasts from SMA patients [19]. Finally, a recent study in SMA
mice found that at end-stage, widespread splicing abnormalities
can be found in several tissues including the spinal cord.
Importantly, different transcripts were found to be altered in a
tissue-specific manner [15].
While both snRNP assembly dysfunction and splicing abnor-
malities have been documented in models of SMA, several
questions remain. It is still unclear whether splicing abnormalities
cause motor neuron loss in SMA, or whether they are a late
occurrence in disease, either as a consequence of spliceosome
dysfunction or the severe physiological alterations secondary to
respiratory distress, hypoxia and malnutrition. If spliceosome
dysfunction is critical for disease pathogenesis, the mechanism of
splicing alterations needs to be further delineated. In addition, the
role of SMN in spliceosome assembly is only one of many
functions that are potentially altered in SMA, including roles in
transcription regulation [20–22], axonal transport of mRNA and
RNPs [23,24] as well as regulation of local translation at the
neuromuscular junction [25].
This study had two aims. First, we wanted to address the
question of whether abnormal splicing events are a cause or
consequence of SMA. We utilised an exon-specific microarray to
examine the transcriptome of spinal cord samples harvested from
SMA and control mice at pre-symptomatic, early symptomatic
and late-symptomatic stages, to test the hypothesis that widespread
alteration of splicing precedes disease onset. Secondly, we used the
difference in temporal mRNA expression pattern between SMA
and control mice to identify neuronal pathways disturbed by SMN
deficiency.
Results
Correlation of mouse phenotype and motor neuron loss
The mouse model used in this study (Smn2/2; SMN2; SMND7)
is the most commonly used model of severe SMA and has been
described previously [26]. The maximum lifespan of SMA mice
was 14 days. Subtle differences in weight compared to the control
littermates (Smn+/+; SMN2; SMND7) were discernible before P7,
but were not reliably predictive of genotype in individual mice
(Figure 1A and 1B). SMN protein levels were markedly reduced in
SMA mice at all time points as measured by Western blot
(Figure 1C) and immunohistochemistry (Figure 1D). At P7 a
failure in the righting reflex became apparent. Importantly, this
coincided with a drop in numbers of large motor neurons in the
spinal cord (Figure 2A and 2B). No discernible differences in
phenotype or pathology were present at P1, indicating that, in the
SMND7 mouse model of SMA, the disease develops in a motor
system in which embryonic development has been relatively
normal. By P13, mice appeared emaciated, were unable to right
themselves, and showed signs of respiratory distress (Figure 1B).
There was a corresponding loss of .30% of lower motor neurons
from the ventral horn in SMA mice. At late-symptomatic stage
(P13), a similar relative loss of motor neurons was evident across
the entire length of the spinal cord, (Figure 2C), justifying the use
of whole spinal cord for RNA analysis. However, absolute
numbers differed depending on the region examined, reflecting
the differential innervation of limb and trunk musculature by
motor neurons originating in the cervical, thoracic or lumbar cord.
Global changes in the spinal cord transcriptome
To understand the scale of change in mRNA expression in the
spinal cord, we first performed gene-level comparisons between
genotypes at each time point, using the core probe sets on the
array and GeneSpring software (Agilent Technologies, Santa
Clara, CA, USA). When using an arbitrary p-value threshold of
0.05 and a fold-change threshold of 1.5 as cut-off for biological
significance, the expression of 142 genes was increased or
decreased in the spinal cord of SMA mice compared with their
control littermates at late-symptomatic stage (P13), with a maximal
fold-change of 3.9 (Table S1). Importantly, the degree of change
between SMA and control mice was much smaller at the pre-
symptomatic (P1) and early-symptomatic (P7) stages, with only 12
and 23 genes changed, respectively (Table 1 and Table 2;
Figure 3A). This finding argues against a critical function of SMN
in transcription regulation, but also shows that if widespread
splicing changes occur in SMA, this does not lead to a pre-
symptomatic systemic change in whole transcript level mRNA
expression, which might be expected if mis-spliced transcripts are
subject to nonsense-mediated decay.
An additional data analysis, which we refer to as the ENSG
analsysis, was performed in which probes were grouped into sets,
Author Summary
The identification of mutations in the Survival Motor
Neuron (SMN) gene as the cause of the severe motor
neuron disorder spinal muscular atrophy is one of a
number of discoveries implicating selective motor neuron
vulnerability to defects in processing of RNA and its
associated ribonucleoprotein complexes. An unresolved
issue is whether loss of the general cellular function of
SMN in spliceosomal assembly, which is predicted to result
in widespread defects in mRNA splicing, is directly
responsible for motor neuron death. We have used exon-
specific microarrays to assess the degree of altered splicing
in the spinal cord in a mouse model of SMA. Our finding
that the vast majority of splicing changes are a late feature
of the disease and may represent a shift to alternative
isoform expression, rather than loss of splicing fidelity,
provides evidence that widespread splicing disturbance is
not a primary feature of the disease pathogenesis but a
secondary effect of cell injury in a late phase of the disease.
However, our study cannot rule out a role for subtle early
changes in one or a few transcripts crucial to motor
neuron survival expressed at low levels or in only in a sub-
population of spinal cord cells.
Alternative Splicing Events Occur Late in SMA
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annotation database [27]. Time point-specific differential expres-
sion between cases and controls was quantified by fitting a linear
model on a gene-by-gene basis [28,29]. Of 21,911 genes
examined, 693 genes exhibited case/control differences at P13,
as opposed to 92 at P7, and 83 at P1 (Figure S1, Tables S2, S3, S4,
see Text S1 for details of the linear model). This is in accordance
with the parallel analysis described above.
We next examined changes between time points for each
genotype. Overall, the number of genes differentially expressed
between time points in control mice was higher by a factor of
ten compared to the number of genes differentially expressed
Figure 1. Phenotype of the SMND7mouse model. (A) Post-natal weight development of SMA (Smn2/2;SMN2;SMND7) and control (Smn+/+;
SMN2;SMND7) mice. Average weight of 4 animals per genotype and time-point; error-bars represent standard deviation of the mean. (B)
Representative images of SMA and control mice littermates at P1, P7, and P13. Scale bar 1 cm. Genotypes can be reliably distinguished
morphologically from P7 onwards. (C) Western blot of whole spinal cord lysates show markedly reduced SMN levels at all measured time points in the
SMA mice. (D) At P13, paucity of large motor neurons in the ventral horn is apparent on H&E stain, with reduced SMN immunoreactivity on
immunohistochemistry.
doi:10.1371/journal.pgen.1000773.g001
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suggesting that the immediate post-natal period is associated
with major changes in spinal cord gene expression in normally
maturing mice.
Exon-level analysis
A key aim of this study was to assess the amount of splicing
variation in the spinal cord of an SMA mouse model compared to
control mouse spinal cord at several time points during disease
progression. Because exon-specific microarrays are relatively
novel, and analysis methods have not been fully developed and
validated, we used two complementary statistical approaches to
investigate the number of differentially expressed exons. First we
used an ANOVA test in GeneSpring (Agilent) to select exons
which show a significant difference between exon-level and
transcript-level signal and then calculated the splicing index (SI)
[30], for these exons. The SI is the logarithm of the ratio of array
probe set intensities (corresponding to expression levels of
individual exons) to overall gene-level expression. So an SI value
of 0 indicates equal expression of a particular exon in relation to
the gene as a whole between genotypes i.e. no differential
alternative splicing. Using a splicing index of |SI|$0.5 as an
arbitrary threshold we identified 252 potential alternative splicing
events at the late-symptomatic stage (P13), but only 5 at the early
symptomatic (P7) and 16 at the pre-symptomatic (P1) stage
(Figure 4A). This initial analysis suggests that alternative splicing
events are a consequence of disease progression in SMA, rather
than the primary cause. Since the splicing index method is known
to lead to inaccuracies if complex splicing patterns are present,
such as splicing of multiple exons in one gene, and might thus
underestimate the level of differential exon use present, we next
performed an analysis comparing expression levels of individual
exons between genotypes at each time point. The rationale for this
is that each instance of differential splicing between genotypes will
lead to at least one exon being differentially expressed. So the
number of differentially expressed exons provides an upper bound
for the number of differential splicing events. In this analysis,
which we refer to as the ENSE analysis, probes were grouped into
sets, each corresponding to an Ensembl exon [27]. Time point-
specific differential expression between cases and controls was
quantified by fitting a linear model on an exon-by-exon basis
[28,29]. The p-value cut-off for significant differences between
genotypes at the exon-level was chosen to balance sensitivity with a
reasonable false discovery rate (FDR), as estimated by a
permutation-based analysis (Text S1 and Table S5). At a p-value
threshold of 1e-4, there were 812 significantly differentially
expressed exons at P13, compared to 66 at P7, and 72 at P1
(Figure 4B, Tables S6, S7, S8); a total of 211,567 exons were
Figure 2. Motor neuron loss in SMA mice. (A) Cresyl violet stain of spinal cord sections showing the ventral horn in control (top) and SMA mice
(bottom), with relative reduction of large Nissl dense cells in SMA mice. (B) Lumbar motor neurons were counted in five animals per genotype at post-
natal days P1, P3, P5, P7, P9, and P13. Motor neuron numbers were equal at the pre-symptomatic time points, while motor neuron loss became
detectable at P7 followed by further decline to approximately 65% of control animal numbers at late-symptomatic stage. Error bars represent the
standard deviation of the mean. (C) At P13, motor neuron loss affects all spinal cord segments, although the absolute number of motor neurons is
higher in the cervical and lumbar region, reflecting the innervation of forelimbs and hind limbs.
doi:10.1371/journal.pgen.1000773.g002
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This provided additional evidence that the vast majority of
alternative splicing events occur at late-stage disease in the
SMND7 mouse model of SMA.
We further observed that for genes with at least one
differentially expressed probe set under the ENSE annotation,
but no significant gene-level change under the ENSG annotation,
i.e. genes for which there is some evidence of differential splicing
events, it is mostly one, and never more than two, exons that are
significantly altered.
To assess whether the differentially expressed exons were
associated with a particular intron type, we cross-referenced our
data with a publicly available database of U12 introns, i.e.
sequences recognised by the U12 snRNA containing minor
spliceosome, but not the U2 snRNA containing major spliceosome
[31]. Overall, the frequency of U12 introns in genes containing
exons differentially expressed between genotypes was 0.19%, as
opposed to the expected frequency of approximately 0.35%
(0.13% at P1, 0% at P7, 0.22% at P13). Moreover, only one gene
(Vash1, ENSG000000712460, Vasohibin-1) contained a differen-
tially expressed exon directly adjacent to an U12 type intron, while
all other exons were remote from U12 type introns. This analysis
suggests that genes spliced by the minor spliceosome are not
preferentially affected by SMA, even though components of the
minor spliceosome were shown to be disproportionately affected
by SMN deficiency [14].
Expression analysis of Smn2/2;SMN2 spinal cord
While the results obtained from the SMND7mouse model
afforded important insights into the dynamics of gene- and exon-
level expression changes over time, to ensure that our findings
were not restricted to this particular transgenic model of SMA,
but applicable to SMA mouse models in general, we performed a
similar analysis on the more severe but genetically less
complicated Smn2/2;SMN2 mouse model of SMA [32]. The
Smn2/2;SMN2 animals, in which complete absence of mouse
Smn is rescued by the introduction of the human SMN2
transgene, have a maximum lifespan of 6 days. Previous studies
showed that at P1, there are normal motor neuron numbers,
whereas at P5, there is about a 35% loss compared to litter mates
with normal mouse Smn (Smn+/+;SMN2) [32]. Early synaptic
abnormalities are seen from P2 in this model [33], although
neuromuscular junctions appear normal at P1, indicating normal
pre-symptomatic development [34]. Exon-array analysis of spinal
cord harvested from pre-symptomatic (P1) and late-symptomatic
(P5) animals mirrored the principal findings in the SMND7m o u s e
at both gene and exon level. When examining gene expression in
Genespring using core probe sets, more changes were present at
late-symptomaticstage than at the pre-symptomatic stage (3 genes
up- or down-regulated at P1, 160 genes up- or down-regulated at
P5 with p#0.05 and fold change .1.5). Even more striking was
the result of the splicing index analysis, which showed 27 potential
alternative splicing events at P5, but none at P1 when choosing a
splicing index cut-off of 0.5.
Table 1. P7 gene-level changes SMA versus control, fold change .1.5, P d 0.05.
Transcripts
Cluster Id
Fold
change Regulation Gene Title Gene Symbol
6809524 3.5 down survival motor neuron 1 Smn1
6969997 2.6 down hemoglobin, beta adult minor chain///hemoglobin,
beta adult major chain
Hbb-b2///Hbb-b1
6805381 2.2 up histone cluster 1, H1c Hist1h1c
6849595 2.2 up cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a
7018366 2.1 up ectodysplasin A2 isoform receptor Eda2r
6961201 1.9 up small nuclear ribonucleoprotein polypeptide A9 Snrpa1
6899760 1.9 up thioredoxin interacting protein Txnip
6755306 1.7 down olfactory receptor 420 Olfr420
6842587 1.7 down Chondrolectin Chodl
6790294 1.7 up chemokine (C-C motif) ligand 3 Ccl3
6764650 1.6 up epoxide hydrolase 1, microsomal Ephx1
6754143 1.6 up ribonuclease L (29,5 9-oligoisoadenylate synthetase-dependent) Rnasel
6926165 1.6 up complement component 1, q subcomponent, beta polypeptide C1qb
6963128 1.6 up olfactory receptor 635 Olfr635
6873271 1.6 down stearoyl-Coenzyme A desaturase 1 Scd1
6785114 1.6 down RAB37, member of RAS oncogene family Rab37
6926166 1.6 up complement component 1, q subcomponent, C chain C1qc
7009748 1.6 down diacylglycerol kinase kappa Dgkk
6788617 1.6 down olfactory receptor 323 Olfr323
6885616 1.5 up RIKEN cDNA 1700007K13 gene 1700007K13Rik
6939671 1.5 down transmembrane protease, serine 11d Tmprss11d
6870375 1.5 up insulin I Ins1
6783144 1.5 down carbonic anhydrase 4 Car4
doi:10.1371/journal.pgen.1000773.t001
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model were not caused by a specific effect of the SMND7
transgene but are likely to be a generalised phenomenon in SMA.
Validation of array findings by RT–PCR, western blotting,
and immunohistochemistry
To validate the findings of our microarray experiments, we
performed semi-quantitative and/or quantitative RT-PCR focus-
sing on genes that showed at least one exon with differential
expression at all time points (Cdkn1, Snrp1a, Chodl, Mccc2,
Uspl1, ChAT, Figure S2). In addition, we performed qRT-PCR
on spinal cord samples obtained from E16 embryos for some of the
targets to examine whether changes were already present pre-
natally. All qRT-PCR results matched the changes at gene-level
seen in the array experiments, underlining the robustness of the
array findings.
Chodl, the gene encoding chondrolectin is a C-type lectin with
unknown in vivo function. Interestingly, in situ hybridisation shows
that this gene is highly expressed in anterior horn cells (Allen Brain
Atlas http://mousespinal.brain-map.org) and might have impor-
tant, if currently unknown, motor neuronal functions. We
observed a progressive reduction in Chodl expression over time.
Of note, the exon array data were indicative of differential
expression of the 39 end of Chodl, and validation by qRT-PCR
using primers spanning both constitutive exons as well as two
alternative 39-terminal exons was in keeping with a preferential
loss of the Chodl -001 isoform (ENSMUST23568) and relative
sparing of Chodl-002 (ENSMUST69148) (Figure 5A and 5B). The
relative reduction of Chodl expression appeared to be spinal cord
specific and could not be demonstrated in either skeletal muscle or
kidney. However, even these tissues showed a trend towards
increased expression of the Chodl-002 isoform in SMA compared
to control mice (Figure 5C). Immunohistochemistry for Chodl
showed strong immunoreactivity of anterior horn cells, in keeping
with the published in situ data. There was reduced Chodl
immunoreactivity in SMA mice, but remaining anterior horn
cells retained substantial Chodl staining, which indicated that the
reduced Chodl expression is at least partially due to loss of motor
neurons (Figure S4).
Uspl1 (ubiquitin specific peptidase like 1), a gene encoding part
of the ubiquitin-dependent protein degradation pathway was
Table 2. P1 gene-level changes SMA versus control, fold change .1.5, P d 0.05.
Transcripts
Cluster Id
Fold
change Regulation Gene Title Gene Symbol
6809524 3.4 down survival motor neuron 1 Smn1
6805381 1.8 up histone cluster 1, H1c Hist1h1c
6805370 1.8 up histone cluster 1, H2bc///histone cluster 1, H2bj///histone cluster 1,
H2bk///histone cluster 1, H2bf///histone cluster 1, H2bl///histone
cluster 1, H2bn///histone cluster 1, H2bb///histone cluster 1, H2be///
histone cluster 1, H2bg///predicted gene, OTTMUSG00000013203
Hist1h2bc///Hist1h2bj///Hist1h2bk///
Hist1h2bf///Hist1h2bl///Hist1h2bn///
Hist1h2bb///Hist1h2be///Hist1h2bg///
RP23-38E20.1
6767782 1.8 up glycoprotein 49 A///leukocyte immunoglobulin-like receptor,
subfamily B, member 4
Gp49a///Lilrb4
6780730 1.6 down olfactory receptor 1393///olfactory receptor 1392 Olfr1393///Olfr1392
6772906 1.6 up laminin, alpha 2 Lama2
6988353 1.6 down olfactory receptor 978 Olfr978
6960235 1.6 up kallikrein 1-related peptidase b21///kallikrein 1-related peptidase b24///
kallikrein 1-related peptidase b11///kallikrein 1-related peptidase b27
Klk1b21///Klk1b24///Klk1b11///
Klk1b27
6973490 1.6 down --- ---
6839959 1.6 down polymerase (RNA) II (DNA directed) polypeptide H Polr2h
6992950 1.5 down ribosomal protein L14///RIKEN cDNA 5830454E08 gene Rpl14///5830454E08Rik
6963442 1.5 down Adrenomedullin Adm
doi:10.1371/journal.pgen.1000773.t002
Figure 3. Global transcriptome changes increase over time. (A)
Number of genes up- or down- regulated more than 1.5 fold in SMA
mice compared to control using a p-value threshold of #0.05. There is a
major increase in gene expression change at late-symptomatic
compared to pre-symptomatic and early-symptomatic stages. (B) Gene
expression changes in control mice (Smn+/+) between time points are
of much larger scale than changes between genotypes.
doi:10.1371/journal.pgen.1000773.g003
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Uspl1 showed a consistent change in both splicing index and
Ensembl exon-level analysis of differential splicing. Uspl1 exon 2
(ENSMUSE00000351955) is a cassette exon absent in trans-
cripts Uspl1-006 (ENSMUST00000121416) and -007 (ENSMU-
ST00000117878). The increased use of Uspl1 exon 2 in the SMA
mice led to an isoform shift with relatively higher levels of exon 2
containing transcripts Uspl1 -001-005 (Figure 6). Of note, this
pattern was much more pronounced in muscle than in spinal cord,
and less evident in kidney (Figure 6B). In spinal cord samples, the
degree of isoform shift was more pronounced at symptomatic than
at pre-symptomatic stages (Figure 6C). Immunohistochemistry for
Uspl1 showed ubiquitous cytoplasmic staining in all spinal cord
cells with grey matter preference. In keeping with the only mild
overall increase in Uspl1 expression at mRNA level (Figure S2F),
no difference in immunoreactivity was evident between genotypes
Figure S4) and Western blotting showed no significant difference
in the main protein isoform identified between genotypes.
Further interesting changes at all time points were detected
including the whole-gene up-regulation of Snrpa1 (average 1.8
fold). Snrpa1 encodes one of the many protein components of the
spliceosomal A complex [34], which is associated with the U2
snRNA. Western blotting showed a consistent small expression
increase (Figure S4). While no other spliceosomal components
were differentially expressed, the Snrpa1 change might reflect a
compensatory response of the cell to Smn deficiency.
Another change included down-regulation of isoforms EN-
SMUST00000091326 and ENSMUST00000022148 of Mccc2,
the gene encoding the methylcrotonoyl-CoA carboxylase beta
chain, a mitochondrial enzyme involved in amino acid metabolism
(Figure S2D). Interestingly, the array data suggest that, while two
Mccc2 isoforms were expressed at lower levels in SMA compared
to controls, a third isoform (ENSMUST00000109383) was in fact
up-regulated. This was confirmed by qRT-PCR and semi-
quantitative PCR (Figure S3).
Pathway analysis
In the SMND7 mouse model, the early postnatal days appeared
particularly relevant to disease development. Our earlier finding of
massive gene expression changes between time points in post-natal
wild-type mice (Figure 3B) indicates that events relevant to disease
in the SMN D7 mouse model coincide with transcriptome changes
associated with normal post-natal development or maturation. To
analyse which pathways were physiologically activated during this
time, we first compared gene expression in control mice (Smn+/+;
SMN2;SMND7) between P1 and P7, and subsequently between P7
and P13. Using GO-Elite software, we identified pathways
enriched with genes involved in spinal cord cell proliferation,
axon development, oligodendrocyte development and myelination
as significantly altered, reflecting physiological events during the
rapid growth of the spinal cord. When the same analysis was
performed for the SMA mice, a strikingly different pattern
emerged. With the exception of two GO IDs pertaining to
nervous system development, all physiologically activated path-
ways were absent in both the P1 v P7 and P7 v P13 analyses
Table 3). To investigate whether this dramatic change in gene
expression pathways was mirrored by a difference in proliferating
spinal cord cells, we performed Western blotting and immunohis-
tochemistry for the proliferation marker PCNA. Our preliminary
results indicate that there is indeed a reduction in the number of
proliferating cells in the SMA spinal cord (Figure S5). At P13,
genes relating to cellular responses to DNA damage became
prominent in the SMA mice, which could not be explained by a
significant amount of spinal cord gliosis (Figure S5). Of note, the
gene with the highest-fold change between genotypes at P13 was
Cdkn1a, a cyclin dependent kinase inhibitor activated by p53 in
response to DNA damage. This analysis suggested that in the
SMND7 mouse model there is an inhibition or a failure of
activation of the normal physiological pathways of post-natal
spinal cord maturation.
Discussion
In this study we undertook a detailed assessment of transcrip-
tional changes over time in the spinal cord of a commonly used
severe mouse model of SMA, using time points correlated with key
phenotypic and pathological changes. We identified alterations in
Figure 4. Exon-level changes are a late occurrence in SMN
deficient mice. (A) Venn diagram depicting potential splicing events
as evidenced by a Splicing Index |SI|.0.5. 252 alternative splicing
events are present at late-symptomatic SMA mice compared to
controls, but only 5 at P7 and 16 at P1. (B) Venn diagram depicting
exon-level changes of Ensembl exons between genotypes at each time
point investigated. At P1, P7, and P13, each of 211,567 exons was tested
for differential expression between SMA and control. 812 exons were
associated with disease status at P13, compared to 72 exons at P1 and
66 exons at P7.
doi:10.1371/journal.pgen.1000773.g004
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pathways in SMA, and showed that splicing alterations are only a
late occurrence in disease.
Survival, weight development and motor phenotype of our
SMND7 mouse colonies were similar to that described by others
[26,35], with a change in outward appearance and development of
motor deficits apparent at P7. Recent studies have identified
morphological changes at the neuromuscular junction as early
events in SMA [33,35] with neurofilament accumulation occur-
ring as early as P5 in the SMND7 model. This structural change at
the distal end of the motor neuron is closely followed in our study
by a significant loss of large motor neurons at P7, indicating that
although synaptic changes are the earliest identified feature of
SMA it ultimately is a disease of the entire lower motor neuron. Of
note, motor neuron loss was present to a similar degree across the
entire spinal cord, in contrast to the previous finding of a rostral-
caudal gradient with relative sparing of the lumbar region [35].
Motor neuron loss at P7 was reflected in the reduction at transcript
level of choline acetyl transferase (ChAT), the key enzyme in
motor neuronal synthesis of acetylcholine (Figure S2E). This
finding, as well as that of reduced levels of Chodl mRNA, which
seems to be highly expressed in anterior horn cells, shows that even
though whole spinal cord was used for the array, important cell-
type specific changes were detectable.
Figure 5. Alternative splicing of Chodl. (A) Graphical output of the exon-level analysis for Chodl. Each column, delineated by bold black lines,
corresponds to the preprocessed data from a single Ensembl exon. The vertical axis displays log2 expression for control (black) and SMA (red) animals,
with each point corresponding to an individual animal. Each column is subdivided by vertical dashed lines into time points P1, P7, and P13 (left to
right). Orange boxes mark those (exon, time point) combinations that exhibit significant differential expression between cases and controls.
Expression of Chodl constitutive exons is reduced progressively from P1 to P13, but there is no difference between SMA and control for the
alternative terminal exon ENSMUSE00000556896 indicating an isoform shift towards Chodl-002 (ENSMUST69148) in the SMA mice. Arrows indicate
location of qRT–PCR primers for validation. (B) qRT–PCR results at P13 showing marked reduction in Chodl when measured using primers located in
the constitutive exons 1–2 and the terminal exon of Chodl-001, while no significant difference of alternative exon ENSMUSE00000556896 exists
between control and SMA (***=p#1e-3). (C) The differential terminal exon usage is also evident in muscle and kidney in SMA mice, although overall
transcript levels are not reduced.
doi:10.1371/journal.pgen.1000773.g005
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are a late occurrence in SMA, and are therefore unlikely to
contribute to early disease pathogenesis. Zhang et al. [15]
described widespread splicing abnormalities in several tissues
including the spinal cord at end-stage disease in the same mouse
model employed in this study and attributed this finding to
dysfunction of the spliceosome secondary to SMN deficiency.
Importantly, even though the time point of analysis is not
absolutely identical to ours, there is considerable overlap between
Zhang et al.’s data set obtained at P11 and our P13 data set, when
raw data are analysed in the same way (Figures S6, S7; Tables S1,
S9, S10, S11). However, it remains unclear from these data
whether splicing abnormalities had preceded the onset of
symptoms, as would be predicted from the crucial role of SMN
in spliceosome assembly, particularly in embryonic and early post-
natal development [13]. In addition, the presence of widespread
splicing defects in organs other than the spinal cord is difficult to
interpret in the light of apparent tissue specificity of the disease if
splicing abnormalities are indeed thought to be relevant to the
mechanism of motor neuron degeneration. To determine the
degree of variation in splicing between SMA and control mice, we
utilised the splicing index, but also examined changes at individual
exons as a measure of the maximum number of alternative splicing
events present. The absolute number of changes found in late-
symptomatic mice was not large given the large number of exons
examined (.200,000). When the same analysis was performed,
comparing between genotypes at pre-symptomatic and early
symptomatic time points, only very few exon-level changes were
present. Importantly, we were able to confirm a similar pattern of
exon expression changes in the more severe Smn2/2;SMN2
mouse model, corroborating our main finding in the SMND7 mice.
Overall, our data indicate that the majority of splicing changes are
not a direct consequence of SMN deficiency, but rather a
consequence of disease progression, probably representing physi-
ological isoform-shifts in response to cell stress. There is evidence
that oxidative stress can induce shifts in alternative splicing, and
that neurons may be more vulnerable to this process than other
cells [36]. We would therefore argue that SMN deficiency to the
degree observed in either the SMND7 or Smn2/2;SMN2 mouse,
although associated with severe reduction in snRNP assembly
capacity in vitro [14], does not lead to a systemic breakdown
of splicing fidelity in vivo until the disease is well established.
While our results do not support the hypothesis that widespread,
systematic splicing abnormalities cause SMA, we cannot rule out
the possibility that splicing of one or several transcripts is critically
affected by SMN deficiency, and that the few splicing changes
observed early in our mice contribute to SMA pathogenesis,
followed by a cascade of loss of splicing fidelity or secondary effects.
In fact, at least one of the genes identified by our array (Uspl1) is
differentially spliced between SMA and control mice even at the
embryonic phase, albeit to a lesser degree than at the symptomatic
stages. Of note, the isoform shift observed in this particular gene is
more pronounced in muscle than in spinal cord, and less marked
in kidney, an organ not affected by SMA pathology.
Independent of whether or not splicing changes are ultimately
responsible for SMA disease initiation, our study identified several
pathways that might shed light on SMA pathogenesis and disease
progression. Analysis of transcriptional changes between genotypes
in this study took place on a background of large scale
physiological changes between time points, reflecting rapid
neuronal development in the early post-natal days. Analysis of
the changes between time points identified several pathways
related to normal neuronal development. Surprisingly, in the SMA
mice the majority of physiological transcriptional changes seen in
control mice were absent even between the early time points P1
and P7. This finding not only indicates that abnormal post-natal
neuronal development might underlie early events in SMA but
might explain general delayed growth and failure to thrive in the
SMA mice.
Figure 6. Alternative splicing of Uspl1. (A) Graphical output of
exon-level analysis for Uspl1. Each column, delineated by bold black
lines, corresponds to the preprocessed data from a single Ensembl
exon. The vertical axis displays log2 expression for control (black) and
SMA (red) animals, with each point corresponding to an individual
animal. Each column is subdivided by vertical dashed lines into time
points P1, P7, and P13 (left to right). Orange boxes mark those (exon,
time point) combinations that exhibit significant differential expression
between cases and controls. Expression of Uspl1 is higher in SMA mice
for all exons, but this difference is more pronounced for the first exon
detected by the array, which corresponds to Uspl1 exon 2
(ENSMUSE00000351955), reflecting a potential alternative splicing
event. (B) Validation of the alternative splicing event by RT–PCR.
Cartoon depicting primer position in Uspl1 exon 1 and 3. RT–PCR was
performed on four biological replicates at P13 showing exon 2 skipping
in control mice, and increased exon 2 usage in SMA mice. The
difference of the exon 2+/exon 2- ratio between genotypes is tissue
specific and most pronounced in muscle and less obvious in kidney. (C)
qRT–PCR results for exon 2 showing increased in Uspl1 exon 2
expression in the SMA mice compared to control. The differential
expression is more pronounced at symptomatic compared to pre-
symptomatic stages.
doi:10.1371/journal.pgen.1000773.g006
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cord and are unable to distinguish which cell types contribute most
to expression changes, even though changes that plausibly
originate from motor neurons, such as ChAT and Chodl, are
clearly present. The neurodevelopmental pathways identified as
altered in our study can be associated with other cell types,
including oligodendrocytes and cells in the posterior spinal cord.
While this is a preliminary finding, it clearly warrants further
studies examining the role of non-motor neuronal cells in SMA.
Human autopsy cases indicate involvement of sensory neurons in
the dorsal root ganglia, Clarke’s column and the thalamus in SMA
[37–40], although the majority of studies were undertaken before
the molecular diagnosis of SMA was available. More recent
clinical studies showed that severe SMN-related SMA is associated
with widespread neuronal degeneration, including sensory path-
ways [41]. Subtle sensory neuron abnormalities have also been
detected in a severe mouse model of SMA [42]. To our
knowledge, however, there is no study systematically investigating
the role of non-motoneuronal cells in SMA spinal cord.
In conclusion, our data show that alternative splicing events
predominantly occur late in SMA, while alterations of post-natal
neurodevelopmental pathways precede overt symptom onset.
Further studies should continue to focus on the role of SMN in
the post-natal maturation and development of the neuromuscular
system including spinal cord motor neurons.
Materials and Methods
Mice
Transgenic Smn
+/2;SMN2;SMND7 [26] mice were maintained
as heterozygous breeding pairs in standard animal facilities in
Oxford. Homozygous Smn
2/2; SMN2; SMND7 mice reached the
Table 3. Comparison of between time point changes in control and SMA mice using GO Elite for .50% and 3 genes changed.
Control SMA
P1 versus P7 P1 versus P7
GOID GO Name GOID GO Name
10456 cell proliferation in dorsal spinal cord 33269 internode region of axon
5243 gap junction channel activity 43209 myelin sheath
5452 inorganic anion exchanger activity
33269 internode region of axon
43209 myelin sheath
14003 oligodendrocyte development
5248 voltage\-gated sodium channel activity
22829 wide pore channel activity
P7 versus P13 P7 versus P13
GOID GO Name GOID GO Name
10456 cell proliferation in dorsal spinal cord 18198 peptidyl\-cysteine modification
6601 creatine biosynthetic process 17154 semaphorin receptor activity
6600 creatine metabolic process 48407 platelet\-derived growth factor binding
32291 ensheathment of axons in the CNS 5248 voltage\-gated sodium channel activity
5243 gap junction channel activity 9065 glutaminefamilyaminoacid catabolicprocess
5452 inorganic anion exchanger activity
33269 internode region of axon
43209 myelin sheath
22010 myelination in the central nervous system
14003 oligodendrocyte development
33270 paranode region of axon
19911 structural constituent of myelin sheath
5248 voltage\-gated sodium channel activity
22829 wide pore channel activity
P7 versus P13
20%-49% changed
GOID GO Name
77 DNA damage checkpoint
32508 DNA duplex unwinding
32392 DNA geometric change
6270 DNA replication initiation
6268 DNA unwinding during replication
Only a selection of GOIDs changed 20%–49% in SMA mice is shown.
doi:10.1371/journal.pgen.1000773.t003
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genotype were sacrificed at age P1, P3, P5, P7, P9, P11 and P13
for motor neuron counts, and 4 mice of each genotype at P1, P7
and P13 for RNA and protein extraction.
Mice were genotyped using DNA extracted from tail-tips and
standard PCR procedures.
For motor neuron counts, mice were terminally anaesthetised
with i.p. pentobarbitone and transcardially perfused with phos-
phate-buffered saline (PBS) followed by 4% paraformaldehyde
(PFA) in PBS.
For RNA and protein extraction, mice were killed by i.p.
injection of pentobarbitone.
Smn
+/2;SMN2 mice (Jackson labs strain no. 005024) were
maintained as heterozygote breeding pairs under standard SPF
conditions in animal care facilities in Edinburgh [43]. Litters
produced from SMA colonies were retrospectively genotyped
using standard PCR protocols (JAXH Mice Resources).
All animal breeding and procedures were performed in
accordance with Home Office and University guidelines.
Motor neuron counts and immunohistochemistry
Spinal cords were dissected, post-fixed in 4% PFA for 2 hours,
cryoprotected in 30% sucrose overnight, embedded in OCT
medium and rapidly frozen in liquid nitrogen-cooled isopentane.
20 mm thick horizontal sections were cut on a cryostat and stained
with 0.5% Cresyl violet with 0.04% acetic acid. A minimum of 30
non-adjacent sections covering the entire spinal cord segment of
interest were scrutinised for large, polygonal, Nissl positive cells in
the ventral horn of the spinal cord anterior to the central canal.
Only cells with a clearly present nucleolus were counted to avoid
double counting of neurons. Motor neuron counts were performed
blinded to genotype. At P13, cords were macroscopically divided
into cervical, thoracic and lumbar segments using the cervical and
lumbar enlargements as landmarks. For the time-course, only
lumbar spinal cord was utilised.
6 mm thick paraffin section were cut and stained with standard
Haematoxylin and Eosin. For immunohistochemistry, sections
were incubated with the primary antibody (mouse anti-SMN
antibody (1:320, BD Transduction lab), rabbit anti-Uspl1 (1:600,
Santa Cruz), mouse anti-Chodl (1:200, abcam), rabbit anti-PCNA
(1:2500, abcam), goat anti-Chat (1:400, Chemicon) for 40 minutes
at room temperature or at 4uC overnight. Antibody binding was
visualised using a Dako REAL EnVision kit according to
manufacturer’s instructions.
Immunohistochemistry was carried out on several sections taken
from two different paraffin blocks for two animals per genotype.
Representative images are shown.
RNA isolation and microarray
Whole spinal cords were rapidly dissected and snap-frozen on
dry ice. RNA was extracted using the Qiagen RNeasy Mini RNA
extraction kit according to the manufacturer’s instructions.
The quality and RNA integrity was assessed on a BioAnalyzer;
all samples had a RNA Integrity Number (RIN)$9 (Agilent
Laboratories, US). 1 ug starting RNA was ribosome depleted
using the Ribominus Human/MouseTranscriptome Isolation kit
(Invitrogen). Labelled sense ssDNA for hybridization was gener-
ated with the Affymetrix GeneChip WT sense target labelling and
control reagents kit (Affymetrix, UK) according to the manufac-
turer’s instructions. Sense ssDNA was fragmented and the
distribution of fragment lengths was measured on the BioAnalyzer.
The fragmented ssDNA was labelled and hybridized to the
Affymetrix GeneChip Mouse Exon 1.0 ST Array (Affymetrix).
Chips were processed on an Affymetrix GeneChip Fluidics Station
450 and Scanner 3000.
Microarray gene expression and pathway analysis
For the gene-level analysis, core probe sets which map to the
same transcript cluster were grouped together and RMA (Robust
multi-array analysis) [44] normalised in GeneSpring GX10.1.02.
Differentially expressed genes were identified using an unpaired
t-test; selecting genes with 1) a p-value less than or equal to an
arbitrary threshold of 0.05 and 2) a fold change difference between
genotypes $1.5. The selected genes were sorted according to gene
ontology using GenMAPP’s GO-Elite (http://www.genmapp.
org/go_elite/go_elite.html). Only MAPPFinder ontologies with
$3 genes changing and a permuted p-value of #0.05 were
reported.
Splicing index
At the exon level, core probe sets were PLIER (Probe
Logarithmic Intensity Error) normalised in GeneSpring GX
10.1.02 (Agilent). Transcript probe sets that had detection above
background (DABG) p-value#0.05 in both SMA and control
groups were retained. An ANOVA test was used to identify
significant differences between exon-level signal and transcript
level signal. As recommended in the Affymetrix White Paper
[44,45], exon level probe sets exhibiting exon-to-transcript
intensity ratios .5 were excluded from the ANOVA (where
log2[exon-to-transcript ratio]=log2[exon expression]2log2[tran-
script expression]). This filter removed probes with high
background and cross-hybridisation potential. The p-value
threshold for the ANOVA was selected to control for a false
discovery rate of 0.05 using the Benjamini-Hochberg multiple
testing procedure [46]. For exons selected on the basis of the
ANOVA, the spicing index, SI (log2[exon-to-transcript expression
ratio]), was calculated and used as a measure of differential
splicing between genotypes. See [45,47] for further details. A
significantly differentially spliced exon was defined to be one
having both an FDR-controlled ANOVA p-value#0.05 and
|SI|$0.5 (on the log scale, corresponding to a fold change up or
down of approximately 1.4 in the absolute exon/transcript ratio
between genotypes).
Ensembl exon and Ensembl gene expression analysis
CEL files were preprocessed using RMA without background
correction (see Text S1). Publicly available custom chip-definition
files (CDFs) (http://brainarray.mbni.med.umich.edu/Brainarray/
Database/CustomCDF/CDF_download.asp) were used to group
probes into sets. Parallel analyses, based on two different CDFs
were performed. The first CDF, referred to as ENSE, defines a
probe set for each Ensembl exon. The second, ENSG, defines a
probe set for each Ensembl gene [27].
There were 211,567 and 21,911 probe sets for the ENSE and
ENSG analyses respectively. At each probe set, a linear model was
fitted using the limma package (version 2.16.5), to quantify
evidence of genotype differences within each time point (see Text
S1 for details).
False discovery rate analysis
A permutation-based analysis was conducted to estimate the
FDR at a variety of p-value thresholds (see Text S1 and Table
S5).The p-value thresholds selected were 1e-4 for ENSE, and 1e-3
for ENSG, as these thresholds controlled the FDR at a reasonably
low level.
Statistical analyses were performed using R [28], version 2.8.1.
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Snap frozen whole spinal cords were homogenised in RIPA lysis
buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% (w/v) SDS,
1% (v/v) sodium deoxycholate, 1% (v/v) TX-100) and 1% (v/v)
protease inhibitors by sonication at 50% output for 15 sec.
Homogenates were chilled on ice for 20 min and clarified by
centrifugation at 15,800 g for 20 min at 4uC.
Immunoblotting
Protein samples (50 mg/well) were electrophoresed through
12% SDS polyacrylamide gels and transferred to 0.2 mm
nitrocellulose membranes (Millipore). Membranes were blocked
with 5% (w/v) milk powder in TBS-T, pH 8.0, for 1 hr and
incubated with the primary antibody (mouse anti-SMN (1:1,000,
BD Transduction labs), mouse anti-actin (1:1,000, Abcam), rabbit
anti-SNRPA1 (1:1000, abcam), goat anti-CHAT (1:500, Chemi-
con), rabbit anti-USPL1 (1:500, Santa Cruz), rabbit anti-PCNA
(1:200, abcam) in 3% (w/v) BSA in TBST overnight at 4uC. Blots
were probed with HRP-conjugated antibodies (1:10,000, Amer-
sham) and developed using ECL reagents (Amersham).
Western blots were repeated three times on biological replicates,
and representative blots are shown.
RT–PCR and qRT–PCR
RNA was reverse transcribed into cDNA using random
hexamer primers (Invitrogen) and Expand Reverse Transcriptase
(Roche) under standard conditions.
RT-PCR was performed using Taq DNA Polymerase (Sigma)
or Expand High Fidelity PCR system (Roche). Real-time PCR was
performed using Fast SYBR Green chemistry (Applied Biosystems)
and a StepOnePlus Real-time PCR machine (Applied Biosystems).
Real-time PCR Primers were designed with Primer Express
software (Applied Biosystems). Primer concentrations were
optimised to yield low Ct values and minimal primer dimer
formation (commonly 300 nM for both forward and reverse
primers). GAPDH was used as the endogenous control, as there
was no differential expression between genotype in the array and
in qRT-PCR experiments. All primer pairs were tested to have
similar amplification efficiency to GAPDH when tested on serial
cDNA dilutions over 4 log. Fold change was calculated using
standard DDCt calculations. The average fold change per time
point was calculated from four biological replicates at each time
point, and an unpaired two-tailed t-test was used to test for
significantly different gene expression at each time-point. Error
bars represent the standard deviation of the mean.
Supporting Information
Figure S1 Gene level expression changes of Ensembl Genes.
Venn diagram showing the number of differentially expressed
genes at different time points with p#1e-3.
Found at: doi:10.1371/journal.pgen.1000773.s001 (0.22 MB TIF)
Figure S2 Array validation by qRT-PCR. Quantitative RT-
PCR was carried out for all time points on the gene displaying
the highest fold-change in late-symptomatic mice, but no
change at the pre-symptomatic stage (A: Cdkn1a) as well as
several targets found to be differentially expressed at several
time points in the exon array ENSE analysis (B–F: Chodl,
Snrp1a, Mccc2, ChAT, Uspl1). Genes showing differential
expression at P1 were also examined at embryonic stage E16.
Expression is shown relative to control animals. GAPDH was
used as the endogenous control. All qRT-PCR results are in
agreement with the expression change predicted by the array.
Error bars show the standard deviation of the mean for both 4
control and 4 SMA animals per time point. An unpaired t-test
was performed between genotypes to test for significance
(*=p#0.05, **=p#0.01,***=p#1e-3).
Found at: doi:10.1371/journal.pgen.1000773.s002 (0.48 MB TIF)
Figure S3 Differential expression of Mccc2 isoforms. (A)
Graphical output of exon array for Mccc2 (analogous to the
graphical outputs of exon array data in the main manuscript).
(B) At P13, qRT-PCR across exons present in isoforms
Mccc2-201 (ENSMUST00000091326) and Mccc2-202 (ENSMU-
ST00000022148) shows reduced expression in SMA compared to
control (*** p#1e-3, unpaired t-test). (C) While the reduced
expression level of Mccc2-201 and Mccc2-202 is not apparent on
semi-quantitative RT-PCR, the Mccc2-203 isoform ENSMU-
ST00000109383 shows increased expression in SMA.
Found at: doi:10.1371/journal.pgen.1000773.s003 (0.83 MB TIF)
Figure S4 Validation of array findings at protein level. (A)
Immunohistochemistry for Chodl on spinal cord sections of P13
control (A,C) and SMA (B,D) mice shows reduced Chodl
immunoreactivity in the ventral horn of SMA mice, but no
complete loss of Chodl from remaining anterior horn cells. Similar
results are obtained for Chat in control (E,G) and SMA (F,H)
mice. Both Chodl and Chat preferentially stain large anterior horn
cells. Staining for Uspl1 (I,J) shows ubiquitous cytoplasmic Uspl1
expression with preference of the grey matter. (B) Chodl
immunohistochemistry on adult human spinal cord shows very
specific labelling of motor neurons in the ventral horn, supporting
the importance of Chodl for motor neurons. (C) Western blotting
of P13 spinal cord lysates shows reduced Smn and Chat protein
levels, minimal increase of Snrpa1 and no overall difference in
Uspl1. The Uspl1 1 antibody detected multiple bands in keeping
with several known Uspl1 isoforms. MW, molecular weight in
kDa. Scale bars 100 mm.
Found at: doi:10.1371/journal.pgen.1000773.s004 (5.48 MB TIF)
Figure S5 Markers of spinal cord proliferation and gliosis. (A)
GFAP immunohistochemistry of control (A,C) and SMA (B,D)
mice shows no significant difference in spinal cord gliosis at P13.
(B) Western blotting for the cell proliferation marker PCNA
(Proliferating Cell Nuclear Antigen antibody) shows a decrease in
SMA. (C) The specificity of the antibody is shown by staining of
rostral migratory stream cells [(A) no primary antibody, (B) rabbit
anti-PCNA 1:2500] in mouse brain. (D) The entral canal
ependymal zone contains several PCNA positive cells in control
(A,C,E), but not in SMA mice (B,D,F). GFAP, glial fibrillary acidic
protein.
Found at: doi:10.1371/journal.pgen.1000773.s005 (6.13 MB TIF)
Figure S6 Effect of RMA background correction. RMA
background correction applies a smooth, monotonic transforma-
tion from raw probe intensities to corrected probe intensities (this
figure displays this transformation for a single exon array). The
function is linear for medium-to-high intensities, but tends to
stretch out the low-intensity range (the figure is annotated with a
two-fold interval that is mapped to a ten-fold interval).
Found at: doi:10.1371/journal.pgen.1000773.s006 (0.25 MB TIF)
Figure S7 Comparison of P13 data set and Zhang et al data
set. This figure (ENSE (A), ENSG (B)) compares the log2(case/
control fold change) across studies. Only probe sets that are
significantly differentially expressed in at least one study are
included. There is clearly a degree of concordance between the
two studies at these probe sets. In particular, the directionality
of differential expression is extremely consistent across studies
(Table S2).
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Table S1 P13 gene level changes SMA vs control, fold change
.1.5, P#0.05.
Found at: doi:10.1371/journal.pgen.1000773.s008 (0.22 MB
DOC)
Table S2 ENSG analysis P1. Differentially expressed genes at P1
under the ENSG annotation. ENSG data; ‘‘+’’ indicates over-
expression of cases relative to controls.
Found at: doi:10.1371/journal.pgen.1000773.s009 (0.01 MB
CSV)
Table S3 ENSG analysis P1. Differentially expressed genes at P1
under the ENSG annotation.
Found at: doi:10.1371/journal.pgen.1000773.s010 (0.01 MB
CSV)
Table S4 ENSG analysis P7. Differentially expressed genes at P7
under the ENSG annotation.
Found at: doi:10.1371/journal.pgen.1000773.s011 (0.01 MB
CSV)
Table S5 ENSG analysis P13. Differentially expressed genes at
P13 under the ENSG annotation.
Found at: doi:10.1371/journal.pgen.1000773.s012 (0.06 MB
CSV)
Table S6 ENSE analysis P1. Differentially expressed exons at
P1.
Found at: doi:10.1371/journal.pgen.1000773.s013 (0.01 MB
CSV)
Table S7 ENSE analysis P7. Differentially expressed exons at
P7.
Found at: doi:10.1371/journal.pgen.1000773.s014 (0.01 MB
CSV)
Table S8 ENSE analysis P13. Differentially expressed exons at
P13.
Found at: doi:10.1371/journal.pgen.1000773.s015 (0.09 MB
CSV)
Table S9 ENSG comparison P13 vs Zhang et al. Probe sets that
are case/control differentially expressed (p#1e-3) under the
ENSG annotation in at least one of (a) the P13 data, (b) Zhang’s
spinal cord data. Along with the exon/gene IDs and the number of
exons assayed in each gene, the tables include p-values, log2(fold
change), and signed fold change.
Found at: doi:10.1371/journal.pgen.1000773.s016 (0.14 MB
CSV)
Table S10 ENSE comparison P13 vs Zhang et al. Probe sets
that are case/control differentially expressed (p#1e-4) under the
ENSE annotation in at least one of (a) the P13 data, (b) Zhang’s
spinal cord data. Along with the exon/gene IDs and the number of
exons assayed in each gene, the tables include p-values, log2(fold
change), and signed fold change.
Found at: doi:10.1371/journal.pgen.1000773.s017 (0.25 MB
CSV)
Text S1 Statistical analysis of microarray findings; comparison
of the P13 dataset with Zhang et al; primer sequences.
Found at: doi:10.1371/journal.pgen.1000773.s018 (0.09 MB PDF)
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